Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 2,407 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dysplasia Mild Clear all

Conditions: Ulcerative Colitis
Interventions: PF-07054894, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: Kissimmee, Florida • Tampa, Florida • Iowa City, Iowa + 1 more

Conditions: Mild Traumatic Brain Injury (mTBI)
Interventions: Symptom-Targeted Approach to Rehabilitation for Concussion; Behavioral
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Wahiawa, Hawaii • San Antonio, Texas

Conditions: Alzheimer's Disease
Interventions: Donepezil hydrochloride; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Dementia With Lewy Bodies, Parkinson Disease Dementia, Healthy Controls
Interventions: Syn-One skin biopsy, Multi modal MRI, Assessment of dynamic EEG features over 48-hour periods across all study aims, Plasma biomarkers, Galantamine HBr extended-release 8mg capsules (8mg ER).; Procedure · Diagnostic Test · Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 50 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis
Interventions: TVB-2640 - 50 mg; Drug
Lead sponsor: Sagimet Biosciences Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Conditions: Mild Traumatic Brain Injury
Interventions: Quetiapine Fumarate, TAU; Drug
Lead sponsor: Foundation for Advancing Veterans' Health Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Albuquerque, New Mexico • San Antonio, Texas

Conditions: Mild-moderate Unipolar Depression; Persistent Negative Affect
Interventions: Mindfulness-Based Cognitive Therapy, Focused Attention (FA), Open- Monitoring; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Hepatic Impairment
Interventions: Mezigdomide; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Miami Lakes, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Mild Cognitive Impairment
Interventions: PRISEM Remote; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 50 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Spinal Stenosis, Lumbar Region, With Neurogenic Claudication
Interventions: MILD Procedure, Epidural Steroid Injection; Procedure · Drug
Lead sponsor: Vertos Medical, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 12
States / cities: Chula Vista, California • Fresno, California • Murrieta, California + 9 more

Conditions: Brain Concussion, Mild Traumatic Brain Injury, Motor Disorders, Cognitive Impairment
Interventions: tDCS in Youth with mild traumatic brain injury; Device
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 10 Years to 15 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Mild Cognitive Impairment
Interventions: eggs or egg whites; Other
Lead sponsor: Tufts University; Other
Eligibility: 50 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer Disease
Interventions: Simufilam, Placebo; Drug
Lead sponsor: Cassava Sciences, Inc.; Industry
Eligibility: 50 Years to 87 Years
Enrollment: 804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 74
States / cities: Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 65 more

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Insulin aspart, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 89 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Mild Cognitive Impairment (MCI), Cognitive Dysfunction, Cognitive Disorder, Memory Problems
Interventions: Sabroxy™ (Oroxylum indicum extract), Placebo; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 60 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Mild Traumatic Brain Injury, Distress-based Psychopathology, Chronic Pain
Interventions: Acceptance and Commitment Therapy; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alzheimer's Disease
Interventions: Placebo, Idalopirdine; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 50 Years and older
Enrollment: 933 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 46
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 40 more

Conditions: Hepatic Impairment, Hepatic Function
Interventions: Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Dry Eye Syndromes
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate; Drug
Lead sponsor: Sight Medical Doctors PLLC; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Brentwood, New York

Conditions: Asthma
Interventions: 84ug MAP0020, 42ug MAP0020, 21ug MAP0020; Drug
Lead sponsor: Allergan; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 2
States / cities: Cypress, California • San Antonio, Texas

Conditions: Asthma
Interventions: Iloprost; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Ulcerative Colitis (UC)
Interventions: Ulcerative Colitis Diet, Antibiotic cocktail; Other · Drug
Lead sponsor: Prof. Arie Levine; Government
Eligibility: 8 Years to 19 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatitis, Diet, Food, and Nutrition, Diet, Pancreatic Disease, Enteral Nutrition
Interventions: Regular diet, Clear Liquid Diet; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Colitis, Ulcerative
Interventions: Delayed and extended release mesalazine; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

Symptom-Targeted Approach to Rehabilitation for Concussion (STAR-C)

Neural Correlates In Mild Alzheimer's Disease

Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)

Dismantling Mindfulness: Contributions of Attention vs. Acceptance

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

PRogram to Improve Stress-levels and Enhance Memory

The MiDAS ENCORE Study

Neuromodulation and Neuroimaging in Older Children With Mild Traumatic Brain Injury

The Effect of Daily Consumption of Eggs on Cognitive Function in the Elderly

Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart

A Study of Sabroxy™ (Oroxylum Indicum Extract) for Improving Cognitive Function in Adults With Mild Memory Concerns

One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing FLACS With Premium IOL

Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma

Inhaled Iloprost in Mild Asthma

Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis

Regular vs. Clear Liquid Diet for Mild to Moderate Acute Pancreatitis

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis